Caris Life Sciences

Caris Life Sciences Caris Life Sciences delivers technologies to revolutionize healthcare with market-leading profiling

Caris Life Sciences® is the leading next-generation TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale, clinico-genomic database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next-generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development.

Caris Life Sciences announced the launch of Caris ChromoSeq™, the world’s first Whole Genome Sequencing (WGS) and Whole ...
04/02/2026

Caris Life Sciences announced the launch of Caris ChromoSeq™, the world’s first Whole Genome Sequencing (WGS) and Whole Transcriptome (WTS) assay designed to support the comprehensive clinical genomic evaluation of myeloid malignancies.

“This launch reflects our commitment to delivering a single, integrated genomic solution for patients with hematological cancers that fits into real‑world clinical workflows and provides results fast enough to inform patient care,” said Matthew Oberley, MD, PhD, Senior Vice President, Chief Clinical Officer and Pathologist-in-Chief at Caris.

Learn more: https://www.carislifesciences.com/about/news-and-media/caris-life-sciences-announces-launch-of-caris-chromoseq/

04/01/2026

MI Cancer Seek is an innovative approach to genomic testing designed to help physicians understand and treat cancer more effectively. Available for both adult and pediatric (ages 1-22) patients.

Consult with a healthcare professional about your treatment options. Learn more about this innovative test and view important safety information here: https://bit.ly/4lyGNTR

Caris Life Sciences announced the final results of the Achieve 1 Study. These results represent a major milestone in Car...
03/31/2026

Caris Life Sciences announced the final results of the Achieve 1 Study. These results represent a major milestone in Caris’ goal to detect cancer earlier, through the future launch of Caris Detect™, its multi-cancer early detection (MCED) test.

“With this study, we have validated that our Whole Genome Sequencing approach detects the diverse molecular changes that drive cancer and quantifies performance with greater confidence across stages and patient populations. This data reinforces our view that relying on a narrow slice of biology is not sufficient for early detection,” said David Spetzler, MS, PhD, MBA, President of Caris Life Sciences.

Learn more: https://ow.ly/K8Ss50YBwUa

03/30/2026

On , we recognize the impact of all doctors. Dr. Leo Shunyakov, a Medical Oncologist/Hematologist at Central Care Cancer Center, uses precision oncology to help extend lives and improve cancer care. https://ow.ly/uc3R50Yt7Fu

Caris Life Sciences announced the addition of two new Caris AI Insights™ signatures included in the Caris Molecular Tumo...
03/26/2026

Caris Life Sciences announced the addition of two new Caris AI Insights™ signatures included in the Caris Molecular Tumor Board Report. These signatures assess the risk of patients developing brain metastases in breast and lung cancer. The addition of these two signatures brings the total number of proprietary Caris AI insights to seven, providing deeper insights to physicians and patients.

“Advanced clinical AI tools like Caris AI Insights are helping future-proof cancer care by integrating molecular intelligence into everyday decision making, so that we can personalize care earlier and with greater precision,” said Caris President David Spetzler, MS, PhD, MBA.

Learn more: https://ow.ly/MnMG50YyYtf

Caris Precision Oncology Alliance® (Caris POA®) and collaborators from leading cancer centers will collectively present ...
03/25/2026

Caris Precision Oncology Alliance® (Caris POA®) and collaborators from leading cancer centers will collectively present six studies at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, California, to be held April 17-22, 2026.

“By combining deep genomic profiling with real world clinical evidence, Caris and its collaborators are generating insights that can directly inform treatment decisions and accelerate the development of more effective therapies for patients,” said James Hamrick, MD, MPH, Chairman of the Caris POA.

Learn more: https://ow.ly/aLRu50YynZW

The United States and Canadian Academy (USCAP) of Pathology Annual Meeting is underway in San Antonio, Texas. Stop by Bo...
03/24/2026

The United States and Canadian Academy (USCAP) of Pathology Annual Meeting is underway in San Antonio, Texas. Stop by Booth 512 to meet with the Caris Life Sciences team and explore how our molecular profiling and AI-driven insights are shaping the future of oncology. We’re ready to connect: bit.ly/4uztffB

Caris Life Sciences is recognizing Colorectal Cancer Awareness Month by highlighting the critical role of DPYD testing i...
03/24/2026

Caris Life Sciences is recognizing Colorectal Cancer Awareness Month by highlighting the critical role of DPYD testing in helping to inform treatment for patients with colorectal cancer.

Colorectal cancer remains one of the most common and deadly cancers in the U.S., and recent American Cancer Society data show rising rates in younger adults, highlighting the need for earlier detection, personalized care, and greater awareness of testing that can guide treatment decisions.

“During Colorectal Cancer Awareness Month, it is important to recognize that DPYD testing can provide clinically meaningful information before treatment begins, helping clinicians make more informed decisions for patients who may be candidates for fluoropyrimidine-based therapy, ” said Caris President David Spetzler, MS, PhD, MBA.

Learn more: https://ow.ly/TYjS50YxShv

Caris Life Sciences recently published a study in JAMA Network Open, titled “An AI Approach to Differentiating Lung Squa...
03/20/2026

Caris Life Sciences recently published a study in JAMA Network Open, titled “An AI Approach to Differentiating Lung Squamous Cell Carcinoma From Metastases of Other Origins,” which builds on the body of evidence showing the superiority of Caris’ proprietary and world-leading GPSai® algorithm over traditional diagnostic procedures in correctly diagnosing cancer types.

Learn more: https://ow.ly/5c2Y50YwBTS

Join Caris at the USCAP Annual Meeting in San Antonio, Texas. Visit our team at booth 512 to learn how our comprehensive...
03/17/2026

Join Caris at the USCAP Annual Meeting in San Antonio, Texas. Visit our team at booth 512 to learn how our comprehensive molecular profiling services are helping advance precision medicine and supporting pathologists with deeper insights for clinical decision making.
Learn more and schedule a meeting with our team during the meeting: https://bit.ly/4uztffB

Caris Life Sciences announced the addition of a platinum resistance AI signature to the growing portfolio of Caris AI In...
03/16/2026

Caris Life Sciences announced the addition of a platinum resistance AI signature to the growing portfolio of Caris AI Insights™. This new signature is designed to predict early platinum resistance in patients with high-grade serous ovarian cancer (HGSOC) and provides clinicians with unprecedented molecular insight into how long a patient may benefit from first-line platinum-based chemotherapy.

“The ability to anticipate which patients are likely to develop early platinum resistance has the potential to significantly improve how we approach ovarian cancer care,” said David Spetzler, MS, PhD, MBA, Caris President.

Learn more: https://ow.ly/k4km50YtNtz

Join pathology leaders and industry collaborators for a Caris Research Collaborators Networking Reception on Monday, Mar...
03/15/2026

Join pathology leaders and industry collaborators for a Caris Research Collaborators Networking Reception on Monday, March 23, 2026. The evening includes networking and a short panel discussion on real world, high impact pathology research conducted with Caris Precision Oncology Alliance institutions and biopharma partners.

Learn more and register: https://www.carislifesciences.com/poa-uscap-2026/

Address

-
Irving, TX
75039

Opening Hours

Monday 7am - 7pm
Tuesday 7am - 7pm
Wednesday 7am - 7pm
Thursday 7am - 7pm
Friday 7am - 7pm

Telephone

+18889798669

Website

Alerts

Be the first to know and let us send you an email when Caris Life Sciences posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

#WeAreCarisLS

We believe in more treatment options. Because more treatment options, can mean more time with the ones you love the most.

We’re dedicated to fulfilling the promise of precision medicine and changing the face of cancer care by providing the personalized and precise information needed to guide individualized treatment options. Learn more about our suite of market-leading molecular profiling offerings that assesses DNA, RNA and proteins to reveal the highest quality molecular blueprint so you can determine treatment options with confidence: www.carismolecularintelligence.com.